Table of Contents
Overview
New York, NY – August 12, 2025 : The Global Plasma-Derived Medicine Market is projected to reach around US$ 36.6 Billion by 2034. This is a significant rise from US$ 16.8 Billion in 2024. The market is expected to grow at a steady compound annual growth rate (CAGR) of 8.1% between 2025 and 2034. In 2024, North America led the market with a revenue of US$ 6.2 billion, accounting for more than 37.2% of the global market share.
Increasing demand for life-saving treatments is a key driver of the plasma-derived medicine market. These medicines include immunoglobulins, clotting factors, and albumin. They play a vital role in treating serious diseases such as immune deficiencies, hemophilia, and liver disorders. The growing prevalence of chronic conditions worldwide further fuels this demand, highlighting the critical importance of plasma-derived therapies in modern healthcare.
Advancements in biotechnology have greatly enhanced plasma-derived medicine production. Innovations allow for better quality and safer therapies. Personalized medicine also supports market growth by tailoring treatments to patients’ genetic and immunological profiles. This approach improves treatment effectiveness. Additionally, increasing voluntary blood donations, especially in countries like China, have boosted plasma supply. China saw a 5.9% rise in blood donations in 2023, reaching 16.99 million, which directly impacts plasma availability.
Emerging markets show strong potential for growth in plasma-derived medicines. Improvements in healthcare infrastructure and awareness contribute to rising demand. New technologies, such as recombinant methods, reduce reliance on human plasma by producing clotting factors and proteins artificially. These developments enhance safety and scalability. Investments in plasma fractionation technologies also increase production efficiency. Together, these factors are driving significant advancements in the plasma-derived medicine industry.
The plasma-derived medicine market continues to evolve with ongoing innovation and rising global demand. Enhanced production methods and expanding access make treatments more available worldwide. As chronic diseases become more common, plasma therapies are vital for improving patient outcomes. The focus on personalized and biotechnological advancements will further support sustainable growth. Overall, the market is set to offer better, safer, and more effective treatment options for patients across various regions in the coming years.
Key Takeaways
- In 2024, the global plasma-derived medicine market generated US$ 16.8 billion and is forecasted to reach US$ 36.6 billion by 2034.
- The market is growing at a compound annual growth rate (CAGR) of 8.1%, reflecting steady expansion over the next decade.
- Immunoglobulin dominated the product segment in 2023, accounting for 60.5% of the plasma-derived medicine market share.
- Key applications include bleeding disorders, multifocal motor neuropathy, liver disease, with bleeding disorders holding a dominant 63.5% share.
- North America led the global market in 2023, capturing 37.2% of total revenue, driven by advanced healthcare infrastructure and demand.
Regional Analysis
North America leads the Plasma Derived Medicine Market with a 37.2% revenue share. This growth is driven by rising diagnoses of rare and chronic diseases requiring plasma therapies. Conditions like primary immunodeficiencies, hemophilia, and neurological disorders increase demand. The Immune Deficiency Foundation estimates 250,000 people in the US have primary immunodeficiency, many needing immunoglobulin therapy. Strong plasma collection efforts in the US and Canada help meet this demand. Leading companies like Grifols and CSL Behring report solid revenue growth from immunoglobulin products, supporting market expansion.
The Asia Pacific region is set to grow at the highest CAGR during the forecast period. This is due to improved healthcare infrastructure and increased diagnosis rates. Governments in countries like China and Japan focus on rare disease management and plasma-derived treatments. Policies aim to boost access to these medicines. Major manufacturers, including Takeda, show strong performance in Asia Pacific markets. Combined industry and government efforts will accelerate the adoption of plasma therapies across the region.
Segmentation Analysis
Immunoglobulin leads the plasma-derived medicine market with a 60.5% share. It is widely used to treat primary and secondary immunodeficiencies, autoimmune diseases, and neurological disorders. The rising prevalence of immune system disorders fuels demand. Advances in immunoglobulin therapy, such as subcutaneous formulations, make self-administration easier for patients. This convenience is expected to boost adoption. Growing awareness of its effectiveness in reducing infections and improving life quality will also drive market growth globally, especially in developing regions.
Bleeding disorders, including hemophilia, dominate the plasma-derived medicine applications segment, accounting for 63.5% of the market. Improved genetic testing has increased diagnoses, especially in emerging markets. Innovations like longer-acting clotting factors and combination therapies enhance treatment effectiveness. The shift toward personalized and preventive therapies is also boosting demand. Increasing patient numbers requiring regular infusions will further drive growth. Investment in bleeding disorder research ensures this segment remains a strong market driver worldwide.
Key Players Analysis
Key players in the plasma-derived medicine market use multiple strategies to boost growth. They expand product portfolios to cover immune deficiencies, bleeding disorders, and neurological diseases. Heavy investment in research and development helps create better treatments and improve manufacturing processes. Companies also form strategic partnerships with healthcare providers, biotech firms, and academic institutions to drive innovation. Expanding production capacity and managing supply chains effectively enable them to meet rising global demand.
Takeda Pharmaceutical Company stands out as a global leader in plasma-derived therapies. The company offers a wide range of products targeting immunodeficiencies and bleeding disorders. Takeda emphasizes innovation and patient-centered care to expand its portfolio and enhance treatment outcomes. With strong global operations and a robust pipeline of therapies, Takeda remains a dominant force in this growing market. Regulatory compliance and patient access programs further support its market position.
Emerging Trends
- Growing Focus on Immunoglobulins: Immunoglobulins are one of the most important plasma-derived products today. Doctors and patients are increasingly turning to these therapies for treating immune system disorders. This growing reliance is driving significant growth in this market segment. Immunoglobulins help boost the body’s ability to fight infections and manage autoimmune conditions. As awareness of their benefits spreads, demand continues to rise. This makes immunoglobulins a key focus area for manufacturers and healthcare providers alike.
- Technological Advances in Plasma Collection and Processing: Plasma collection and processing methods are improving rapidly. New technologies make these processes safer and more efficient. Better techniques help produce high-quality plasma-derived medicines without delays or risks. This allows companies to meet the rising demand while maintaining strict safety standards. Innovations in automation and purification also contribute to improved production. Overall, these advances strengthen the supply chain and support market growth.
- Expansion into New Therapeutic Areas: Plasma-derived medicines are being tested for new diseases beyond their traditional uses. This expansion opens the door to treating conditions that previously had few or no treatment options. For example, researchers are exploring plasma therapies for neurological and rare disorders. This broadens the potential market and offers hope to many patients. The development of these new applications could transform the future of plasma medicine.
- Increasing Global Awareness and Access: Awareness of plasma-derived medicines is growing worldwide. More countries, including many developing nations, are improving their plasma collection systems. This helps make these treatments available to a wider population. Better infrastructure and training allow for safer and more efficient plasma donation. Expanding access ensures that more patients can benefit from life-saving therapies. This trend supports the global growth of the plasma-derived medicine market.
- Focus on Personalized and Subcutaneous Therapies: There is a clear shift toward treatments that patients can use at home. Subcutaneous immunoglobulin therapies are gaining popularity because they are easier to administer than traditional intravenous methods. These therapies improve patient comfort and convenience. Personalized treatment plans also ensure better adherence and outcomes. This move towards home-based care helps reduce hospital visits and costs, making treatment more accessible and patient-friendly.
Use Cases
- Treatment of Immune Deficiency Disorders: Many patients have weak or missing immune systems. They rely on plasma-derived immunoglobulins to fight infections. These immunoglobulins act like antibodies that help the body defend itself. Without them, patients can get frequent and severe infections. Plasma-derived immunoglobulins provide these patients with the protection they need. This treatment helps improve their overall health and quality of life. It is a crucial therapy for people with primary or secondary immune deficiencies. Doctors widely use plasma-derived immunoglobulins to boost immunity and reduce the risk of illness in these vulnerable patients.
- Hemophilia and Bleeding Disorders: People with hemophilia have trouble controlling bleeding. Plasma-derived clotting factors are vital for them. These clotting factors help stop bleeding quickly during episodes. Without treatment, bleeding can cause severe complications, even be life-threatening. Plasma therapies make it possible to manage bleeding safely and effectively. Patients can live healthier lives with fewer bleeding episodes. These clotting factors are also used to prevent bleeding before surgeries or injuries. Thanks to plasma-derived clotting factors, people with bleeding disorders enjoy better care and improved daily functioning.
- Autoimmune Disease Management: Some autoimmune diseases cause the immune system to attack the body’s own tissues. Plasma-derived products can help regulate this immune response. For example, patients with Guillain-Barré syndrome benefit from these treatments. The plasma products work by calming down an overactive immune system. This helps reduce symptoms like muscle weakness and numbness. By balancing the immune system, plasma therapies improve patient comfort and function. These treatments offer hope to those struggling with autoimmune conditions. Doctors often include plasma-derived products as part of the overall disease management plan.
- Support in Critical Care and Surgery: Albumin is a plasma protein commonly used in hospitals during surgery and critical care. It helps maintain blood volume when patients lose fluids or blood. Keeping blood volume stable supports organ function and improves recovery. Albumin acts as a natural blood plasma extender. It helps patients stay stable in critical situations such as trauma or major operations. Using albumin can reduce complications and speed up healing. Hospitals rely on this plasma-derived product to provide better outcomes in emergency and surgical care.
- Neurological Conditions: Certain neurological disorders respond well to plasma therapies. These treatments help by modifying the immune system’s activity. In conditions where the immune system attacks nerves, plasma products can reduce inflammation. This helps lessen symptoms such as pain, weakness, or loss of sensation. Patients often experience improved quality of life after plasma therapy. For example, disorders like chronic inflammatory demyelinating polyneuropathy (CIDP) benefit from these treatments. Plasma therapies are an important part of managing neurological diseases linked to immune dysfunction.
Conclusion
The plasma-derived medicine market is growing steadily, driven by rising demand for treatments that save lives. Advances in technology and personalized therapies are making these medicines safer and easier to use. More people around the world are gaining access to plasma therapies, especially in emerging regions with improving healthcare systems.
Key products like immunoglobulins and clotting factors remain essential for treating serious health conditions. Companies are investing in research and expanding production to meet the global need. Overall, the market is set to continue its strong growth by offering better, more effective treatments that improve patients’ health and quality of life worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
